fbpx
0f9407626e83ba22b

In Vivo Imaging of AntiI-αFR Car-Engineered NK-92 Cells Displaying Potent Cytotoxicity Against αFR-Positive Ovarian Cancer

In Vivo Imaging of AntiI-αFR Car-Engineered NK-92 Cells Displaying Potent Cytotoxicity Against αFR-Positive Ovarian Cancer Download Document Here Introduction Ovarian cancer is the most common and most lethal among gynecologic tumors. Folate receptor alpha (FRα), a tumor-associated antigen Folate Receptor alpha, has been reported to be overexpressed in solid tumors like ovarian cancers. The

By |2022-04-04T10:03:15-04:00February 23rd, 2022|Categories: Articles, Cancer Research, Imaging, Optical|Tags: , , , |Comments Off on In Vivo Imaging of AntiI-αFR Car-Engineered NK-92 Cells Displaying Potent Cytotoxicity Against αFR-Positive Ovarian Cancer

(December 2, 2021) The Bench to Bedside Series: Preclinical Cancer Research with Scintica

In this webinar we will discuss the following topics: • Introduction To Cancer Research • What does “Bench to Bedside” mean? • In vitro characterization • Rapid throughput screening • Quantitative tools • Moving towards translation Overview: The goal of this webinar will be to provide a high-level overview of the various stages of preclinical

By |2022-01-07T11:11:29-05:00November 2nd, 2021|Tags: , , , |Comments Off on (December 2, 2021) The Bench to Bedside Series: Preclinical Cancer Research with Scintica

(May 6, 2021) Precision Oncology: Combining Orthotopic-PDX Models and MRI, Moving Research Forward, and Improve Clinical Outcomes

Overview: Certis Oncology Solutions is a precision oncology and translational science company. It works directly with cancer patients and their oncologists to help determine the best therapies for individuals, and also partners with pharmaceutical companies to help develop the next generation of anticancer therapies.  Certis’s approach to studying drug efficacy is rooted in

By |2021-11-23T13:22:29-05:00May 4th, 2021|Categories: Animal Models, Event, Imaging, Mouse, MRI, Optical, Past Webinar, Rat|Tags: , , , , , , , |Comments Off on (May 6, 2021) Precision Oncology: Combining Orthotopic-PDX Models and MRI, Moving Research Forward, and Improve Clinical Outcomes
Go to Top